13F Pro13F Pro

Opaleye Management Inc.

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1595855
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare98.6%$1.1B
  • Materials1.4%$15.3M

AUM History

13fpro.ai/research/fund/opaleye-management-inc-1595855

Conviction and streaks

Concentrating · top 10 = 64.8%

From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.

LQDA$LQDAConviction hold17.7% weight · held 10 quartersETON$ETONConviction hold9.4% weight · held 10 quartersHROW$HROWConviction hold9.2% weight · held 10 quartersIRON$IRONConviction hold5.7% weight · held 6 quartersAPGE$APGEConviction hold4.7% weight · held 4 quartersIRON$IRONAccumulating+341% shares · 3 quarters runningURGN$URGNAccumulating+555% shares · 3 quarters runningACOG$ACOGAccumulating+2415% shares · 3 quarters runningXOMA$XOMAAccumulating+33% shares · 3 quarters runningCABA$CABAAccumulating+378% shares · 3 quarters runningRYTM$RYTMTrimming-87% shares · 4 quarters runningHROW$HROWTrimming-39% shares · 2 quarters runningANNX$ANNXTrimming-34% shares · 2 quarters runningFBIO$FBIOTrimming-18% shares · 2 quarters runningDERM$DERMTrimming-64% shares · 2 quarters running

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/opaleye-management-inc-1595855

Opaleye Management Inc. 13F holdings — Q2 2026

$1.1B portfolio (+45.4% QoQ) · 58 holdings · Q2 2026 13F · top 10 are 65% of the stock portfolio

All holdings — Opaleye Management Inc. (Q2 2026)

58 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
IMMX$IMMXImmix Biopharma, Inc.$24.2MNew
CBIO$CBIOCRESCENT BIOPHARMA, INC.$23.7M+0.5%
STOK$STOKStoke Therapeutics, Inc.$22.9M—
ACOG$ACOGAlpha Cognition Inc.$20.9M+13%
EWTX$EWTXEdgewise Therapeutics, Inc.$20.3M—
RVMD$RVMDRevolution Medicines, Inc.$18.7M—
GLUE$GLUEMonte Rosa Therapeutics, Inc.$18.0MNew
ALMS$ALMSALUMIS INC.$15.5M—
CDXS$CDXSCODEXIS, INC.$15.3M—
REPL$REPLReplimune Group, Inc.$15.3MNew
XOMA$XOMAXOMA Royalty Corp$14.4M+13%
MBX$MBXMBX Biosciences, Inc.$14.4M—
RYTM$RYTMRHYTHM PHARMACEUTICALS, INC.$13.6M-0.4%
EDIT$EDITEditas Medicine, Inc.$12.5M+100%
PTGX$PTGXProtagonist Therapeutics, Inc$12.3M—

What changed in Q2 2026

Against the previous quarter's 13F: 13 new, 15 added to, 13 trimmed, 9 sold out. Share-count changes; largest moves by dollar size first.

New positions (13)

  • IMMX$IMMXImmix Biopharma, Inc.$24.2M

    first bought this quarter

  • GLUE$GLUEMonte Rosa Therapeutics, Inc.$18.0M

    first bought this quarter

  • REPL$REPLReplimune Group, Inc.$15.3M

    first bought this quarter

  • VSTM$VSTMVerastem, Inc.$6.9M

    first bought this quarter

  • PHAT$PHATPhathom Pharmaceuticals, Inc.$2.0M

    first bought this quarter

  • INBX$INBXInhibrx Biosciences, Inc.$1.9M

    first bought this quarter

+7 more in the Excel export

Added to (15)

  • IRON$IRONDisc Medicine, Inc.+103%

    now $62.5M · held 4+ qtrs, 3 adds in a row

  • MGTX$MGTXMeiraGTx Holdings plc+67%

    now $48.0M · held 3 qtrs, 3 adds in a row

  • CABA$CABACabaletta Bio, Inc.+180%

    now $12.0M · held 4+ qtrs, 3 adds in a row

  • EDIT$EDITEditas Medicine, Inc.+100%

    now $12.5M · held 2 qtrs, 2 adds in a row

  • BBOT$BBOTBridgeBio Oncology Therapeutics, Inc.+1214%

    now $5.3M · held 2 qtrs, 2 adds in a row

  • LYEL$LYELLyell Immunopharma, Inc.+335%

    now $4.8M · held 2 qtrs, 2 adds in a row

+9 more in the Excel export

Trimmed (13)

  • HROW$HROWHARROW, INC.-15%

    now $101.9M · held 4+ qtrs, 2 trims in a row

  • LQDA$LQDALiquidia Corp-4%

    now $195.1M · held 4+ qtrs

  • SNWV$SNWVSANUWAVE Health, Inc.-69%

    now $3.1M · held 4+ qtrs

  • JBIO$JBIOJade Biosciences, Inc.-66%

    now $3.2M · held 3 qtrs

  • CGON$CGONCG Oncology, Inc.-81%

    now $1.3M · held 4+ qtrs, 2 trims in a row

  • DERM$DERMJourney Medical Corp-64%

    now $2.5M · held 4+ qtrs, 2 trims in a row

+7 more in the Excel export

Sold out (9)

  • CATX$CATXPerspective Therapeutics, Inc.was $19.5M

    held 2 qtrs

  • ASRT$ASRTAssertio Holdings, Inc.was $5.1M

    held 1 qtr

  • STRO$STROSUTRO BIOPHARMA, INC.was $4.7M

    held 2 qtrs

  • TECX$TECXTectonic Therapeutic, Inc.was $3.8M

    held 2 qtrs

  • RIGL$RIGLRIGEL PHARMACEUTICALS INCwas $1.9M

    held 3+ qtrs

  • NXTC$NXTCNextCure, Inc.was $1.5M

+3 more in the Excel export

Firm AUM (Form ADV): $802.8M as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F Opaleye Management Inc. has filed, 39 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Opaleye Management?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of Opaleye Management's top 20 holdings: 57/100 (our AI quality score, weighted by position size; 9 of the 20 are scored)

Top 10 since filing

-24.8%

Value-weighted move of the 10 largest stock positions

Turnover

11%

Last quarter

Top 10 weight

65%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

76%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q3 2025 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Opaleye Management Inc. disclosed 58 positions worth $1.1B in its Form 13F-HR for Q2 2026, led by $LQDA (Liquidia Corp) at 17.7% of the equity portfolio, followed by $ETON and $HROW. During the quarter the fund opened 13 new positions and exited 9 — including a new stake in $IMMX and a full exit from $CATX. The portfolio is most concentrated in Healthcare (98.6% of disclosed assets). All figures are sourced directly from Opaleye Management Inc.’s Form 13F-HR filing with the SEC under CIK 1595855.

Funds like this

managers whose biggest positions overlap Opaleye Management's
Caligan Partners LP$2.13B 13F book · 4 shared top holdingsLQDARVMDMBXIRDMPM BioImpact LLC$1.64B 13F book · 9 shared top holdingsLQDAURGNEWTXRVMDBVF INC/IL$3.91B 13F book · 9 shared top holdingsIRONSTOKRVMDGLUEPERCEPTIVE ADVISORS LLC$6.66B 13F book · 6 shared top holdingsAPGEMGTXEWTXRVMDParadigm Biocapital Advisors LP$5.34B 13F book · 5 shared top holdingsAPGEEWTXRVMDMBXSiren, L.L.C.$4.94B 13F book · 5 shared top holdingsEWTXRVMDSTOKIRON

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Opaleye Management Inc.

13F Pro is an AI hedge fund tracker and stock research platform. For Opaleye Management Inc. (SEC CIK: 1595855), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Opaleye Management Inc.'s portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.